PMC:7195088 / 21737-22029 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"676","span":{"begin":50,"end":58},"obj":"Species"},{"id":"677","span":{"begin":282,"end":290},"obj":"Species"},{"id":"801","span":{"begin":24,"end":34},"obj":"Chemical"},{"id":"802","span":{"begin":206,"end":216},"obj":"Chemical"},{"id":"803","span":{"begin":221,"end":239},"obj":"Chemical"},{"id":"804","span":{"begin":244,"end":254},"obj":"Chemical"},{"id":"805","span":{"begin":260,"end":278},"obj":"Chemical"},{"id":"942","span":{"begin":64,"end":72},"obj":"Disease"}],"attributes":[{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"Tax:9606"},{"id":"A677","pred":"tao:has_database_id","subj":"677","obj":"Tax:9606"},{"id":"A801","pred":"tao:has_database_id","subj":"801","obj":"MESH:C000606551"},{"id":"A802","pred":"tao:has_database_id","subj":"802","obj":"MESH:C000606551"},{"id":"A803","pred":"tao:has_database_id","subj":"803","obj":"MESH:D006886"},{"id":"A804","pred":"tao:has_database_id","subj":"804","obj":"MESH:C000606551"},{"id":"A805","pred":"tao:has_database_id","subj":"805","obj":"MESH:D006886"},{"id":"A942","pred":"tao:has_database_id","subj":"942","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T13","span":{"begin":173,"end":178},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T106","span":{"begin":64,"end":72},"obj":"Disease"}],"attributes":[{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T106","span":{"begin":155,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0050154"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T242","span":{"begin":24,"end":34},"obj":"Chemical"},{"id":"T243","span":{"begin":206,"end":216},"obj":"Chemical"},{"id":"T244","span":{"begin":221,"end":239},"obj":"Chemical"},{"id":"T245","span":{"begin":244,"end":254},"obj":"Chemical"},{"id":"T246","span":{"begin":260,"end":278},"obj":"Chemical"}],"attributes":[{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A246","pred":"chebi_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}

{"project":"LitCovid-sentences","denotations":[{"id":"T157","span":{"begin":8,"end":73},"obj":"Sentence"},{"id":"T158","span":{"begin":74,"end":117},"obj":"Sentence"},{"id":"T159","span":{"begin":118,"end":189},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"day 14.\n• Comparison of remdesivir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04280705, recruiting). Primary endpoint: severity rating on a 8-point ordinal scale at day 15.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients w"}